Skip to content

ImmunityBio, Inc. IBRX Debt-to-assets

Debt-to-assets at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
0.5×0.0×
Johnson & Johnson logo
Johnson & JohnsonJNJ
0.3×0.0×
Merck & Co. logo
Merck & Co.MRK
0.4×+0.1×
Gilead Sciences logo
Gilead SciencesGILD
0.4×0.0×
Immunovant, Inc. logo
Immunovant, Inc.IMVT
0.0×
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
0.0×

Other financials

Income statement

See full
Revenue$44.2M+168%
Gross profit$44.0M+167%
Operating income-$69.8M-8.3%
Net income-$632.8M-388%
EPS (diluted)-$0.62-313%

Balance sheet

See full
Cash & equivalents$205.2M+238%
Total debt$445.4M+32.2%
Total equity-$870.0M-47.1%
Total assets$646.6M+113%

Cash flow

See full
Operating cash flow-$75.4M+12.3%
CapEx$1.8M+58.4%
Free cash flow-$77.1M+11.4%

Valuation

See full
Market cap$7.71B+208%
Enterprise value$7.95B+187%
P/S54.7×-25.4×

Profitability

See full
Gross margin99.3%-0.5pp
Operating margin-185.4%-83.3pp
Net margin-606.2%-212pp
FCF margin-212%-95.8pp

Returns & leverage

See full
Return on equity-119.3%
Debt / equity0.1×
Current ratio6.7×+4.4×

Where this comes from

Calculated from ImmunityBio, Inc.’s reported figures.

Based on the most recent quarter.

The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ImmunityBio, Inc.'s debt-to-assets?
ImmunityBio, Inc. (IBRX) reported debt-to-assets of 0.7× in Q1 2026.
How has ImmunityBio, Inc.'s debt-to-assets changed year-over-year?
ImmunityBio, Inc.'s debt-to-assets decreased by 37.9% year-over-year, from 1.1× to 0.7×.
What is the long-term trend for ImmunityBio, Inc.'s debt-to-assets?
Over 5 years (2020 to 2025), ImmunityBio, Inc.'s debt-to-assets has grown at a 60.2% compound annual growth rate (CAGR), from 0.1× to 0.7×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.